(MedPage Today) — DENVER — Two drug candidates to expand oral therapy options for psoriasis had similar and consistent performances in separate phase III clinical trials reported here.
The allosteric TYK2 inhibitor zasocitinib achieved at…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
